Proteolysis of a histone acetyl reader, ATAD2, induces chemoresistance of cancer cells under severe hypoxia by inhibiting cell cycle progression in S phase

[1] C.J. Yeom, Y. Goto, Y. Zhu, M. Hiraoka, H. Harada, Microenvironments and

cellular characteristics in the micro tumor cords of malignant solid tumors, Int. J.

Mol. Sci. 13 (2012) 13949–13965.

[2] R.H. Thomlinson, L.H. Gray, The histological structure of some human lung cancers

and the possible implications for radiotherapy, Br. J. Cancer 9 (1955) 539–549.

[3] L.H. Gray, A.D. Conger, M. Ebert, S. Hornsey, O.C. Scott, The concentration of

oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy, Br.

J. Radiol. 26 (1953) 638–648.

[4] C.E. McAleese, C. Choudhury, N.J. Butcher, R.F. Minchin, Hypoxia-mediated drug

resistance in breast cancers, Cancer Lett. (2020).

[5] H. Doktorova, J. Hrabeta, M.A. Khalil, T. Eckschlager, Hypoxia-induced

chemoresistance in cancer cells: the role of not only HIF-1, Biomed. Pap. Med. Fac.

Univ. Palacky Olomouc Czech Repub. 159 (2015) 166–177.

[6] X. Jing, F. Yang, C. Shao, K. Wei, M. Xie, H. Shen, Y. Shu, Role of hypoxia in cancer

therapy by regulating the tumor microenvironment, Mol. Cancer 18 (2019) 157.

[7] D. Hussein, E.J. Estlin, C. Dive, G.W. Makin, Chronic hypoxia promotes hypoxiainducible factor-1alpha-dependent resistance to etoposide and vincristine in

neuroblastoma cells, Mol. Cancer Therapeut. 5 (2006) 2241–2250.

[8] G.L. Wang, G.L. Semenza, General involvement of hypoxia-inducible factor 1 in

transcriptional response to hypoxia, Proc. Natl. Acad. Sci. U. S. A. 90 (1993)

4304–4308.

[9] H. Harada, Hypoxia-inducible factor 1-mediated characteristic features of cancer

cells for tumor radioresistance, J. Radiat. Res. 57 (Suppl 1) (2016) i99–i105.

[10] Y. Goto, L. Zeng, C.J. Yeom, Y. Zhu, A. Morinibu, K. Shinomiya, M. Kobayashi,

K. Hirota, S. Itasaka, M. Yoshimura, K. Tanimoto, M. Torii, T. Sowa, T. Menju,

M. Sonobe, H. Kakeya, M. Toi, H. Date, E.M. Hammond, M. Hiraoka, H. Harada,

UCHL1 provides diagnostic and antimetastatic strategies due to its

deubiquitinating effect on HIF-1alpha, Nat. Commun. 6 (2015) 6153.

[11] G.L. Semenza, Molecular mechanisms mediating metastasis of hypoxic breast

cancer cells, Trends Mol. Med. 18 (2012) 534–543.

[12] G.L. Semenza, Regulation of cancer cell metabolism by hypoxia-inducible factor 1,

Semin. Cancer Biol. 19 (2009) 12–16.

[13] G.L. Semenza, Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer 3 (2003)

721–732.

[14] S.V. Karakashev, M.J. Reginato, Progress toward overcoming hypoxia-induced

resistance to solid tumor therapy, Cancer Manag. Res. 7 (2015) 253–264.

[15] N. Rohwer, T. Cramer, Hypoxia-mediated drug resistance: novel insights on the

functional interaction of HIFs and cell death pathways, Drug Resist. Updates 14

(2011) 191–201.

84

...